CardioDiagnostics Inc.

Cardio Diagnostics is a commercial-stage biotech company with a mission to transform cardiovascular care from reactive to proactive using its unique AI-powered epigenetic platform. The company has achieved key milestones by launching its first commercial tests, Epi+Gen CHD and PrecisionCHD, targeting the massive and underserved market for early coronary heart disease detection. Its strategy involves a multi-pronged commercial approach, engaging healthcare providers, employers, and biopharma partners to drive adoption and generate data-driven insights across the care continuum.

An AI-driven Multi-Omics Engine that integrates epigenetic (DNA methylation) and genetic biomarkers with machine learning algorithms to decode the dynamic biology of cardiovascular disease for precise diagnosis and risk assessment.

Cardio Diagnostics competes with traditional diagnostic labs, genetic risk score providers, and AI-imaging analysis firms. Its primary competitive edge is its first-mover, clinically validated AI-epigenetic platform, which offers a dynamic view of cardiovascular biology that static biomarkers cannot provide.